Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.04
<C$0.01(5.56%)
At close: 4:00 PM EST
C$0.04
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
C$11.52M
Enterprise ValueC$34.34M
Total Cash (Recent Filing)C$289.24K
Total Debt (Recent Filing)C$18.65M
Price to Earnings (P/E)―
Beta-3.19
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,283,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Standardized Cannabinoid InputsPharmaCielo’s B2B focus on producing standardized cannabinoid ingredients targets medical and wellness manufacturers that value consistent inputs. This business model can create sticky, recurring institutional demand and scale benefits tied to quality and regulatory compliance, supporting durable revenue opportunities if market access is maintained.
Positive Product-level Gross MarginA reported gross margin of roughly 29% indicates underlying unit economics from cultivation and extraction are positive. Product-level margins suggest the company can generate incremental profitability as sales scale, since manufacturing and processing efficiencies and standardized formulations provide a defensible cost advantage versus low-quality commodity producers.
Improving Cash Burn TrendManagement has materially reduced cash outflows versus the extreme levels seen in 2020–2022, reflecting better cost control or operational progress. This sustained improvement, if continued, lowers refinancing pressure, increases runway, and improves the company’s ability to move toward self-sustaining operations and support needed reinvestment.
Bears Say
Declining And Volatile RevenueTTM revenue declines and volatile historical sales undermine operating leverage: fixed costs remain while utilization falls, eroding the ability to convert positive gross margins into operating profits. Persistent top-line weakness complicates forecasting, reduces bargaining power with customers, and raises the likelihood of needing external funding to bridge gaps.
Negative Equity And High LeverageSignificantly negative equity and debt materially above reported assets signal accumulated losses and an impaired balance sheet. This capital-structure stress limits financial flexibility, increases refinancing and solvency risk, and likely forces dilutive financings or asset disposals to restore solvency, constraining long-term strategic investments.
Persistent Negative Operating Cash FlowOngoing negative OCF and FCF mean the business still consumes cash and cannot self-fund operations or debt service. Until sustained positive cash generation occurs, PharmaCielo will remain dependent on external capital, which is harder to secure given its weak equity position and volatile revenues, increasing execution risk.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$11.52M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is in 43 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 211,283,630 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---